Alfacalcidol

Cas No.:	41294-56-8
Chemical Name:	CID 134688803
Synonyms:	alphacalcidol;VITAMIN D3, 1ALPHA-HYDROXY-;HYDROXYVITAMIN D3;ALFACALCIDOL;1-HYDROXYCHOLECALCIFEROL;1ALPHA-OH-D3;1-alpha-hydroxycholecalciferol;1-ALPHA-HYDROXYVITAMIN D;1(ALPHA)-HYDROXYVITAMIN D3;(1ALPHA,3BETA,5Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1,3-DIOL;(1alpha,3beta,5z,7e)-secocholesta-5,7,10(19)-triene-1,3-diol;1,2-HYDROXY CHOLECALCIFEROL;1-hydroxyvitamind3;7,10(19)-triene-1,3-diol,(1-alpha,3-beta,5z,7e)-10-secocholesta-5;alfarol;alpha-hcl;1-α-Hydroxycholecalciferol;1.alpha.-Hydroxyvitamin D3;1a-Hydroxyvitamin D3;1α-Hydroxycholecalciferol;Alpharol;Bondiol;Etalpha;oxydevit;Un Alfa;unalpha;1α-Hydroxyvitamin D3;(1R,3S,E)-5-((Z)-2-((1R,3aS,7aR)-7a-methyl-1-((R)-6-methylheptan-2-yl)dihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol;CID 134688803
SMILES:	O([H])[C@@]1([H])C([H])([H])[C@@]([H])(C(=C([H])[H])/C(/C1([H])[H])=C(\[H])/C(/[H])=C1/C([H])([H])C([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])[C@]/1([H])C([H])([H])C([H])([H])[C@]2([H])[C@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])O[H]
Formula:	C27H44O2
M.Wt:	400.6371
Purity:	>99%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Alfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3) is a non-selective VDR activator medication. IC50 value: Target: VDR activatorAlfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3) improves mechanical bone strength and bone mass; suppresses osteoclastic bone resorption in vivo.

References:

[1]. Shiraishi et al (2000) Alfacalcidol inhibits bone resorption and stmulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. Journal of Bone and Mineral Research. 15 770. [2]. Ringe JD, Schacht E. et al. Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int. 2004 Jul;24(4):189-97. [3]. Ivarsen P, Povlsen JV, Christensen KL.Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study.Scand J Urol Nephrol. 2012 Jun 25. [4]. Rianthavorn P,et al. Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone.J Pediatr Endocrinol Metab. 2012;25(3-4):307-12. [5]. Ringe JD, Farahmand P, Schacht E.Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.Rheumatol Int. 2012 Apr 8.